ESTRO 37 Abstract book

S889

ESTRO 37

pain and acute toxicity were reported according to CTCAQv4.0 scale. Results From October 2016 to September 2017, 9 patients with a mean age of 84 years (71-90) were treated according to the protocol described above. The improvement / resolution of pain and bleeding were 100% (9/9) and 89% (8/9) respectively. No patient required colostomy during two months after radiotherapy. Acute toxicity ≤ grade 2 was 22% (genitourinary) and 44% (gastrointestinal), without grade 3 or 4 toxicities. No treatment was discontinued because toxicity. Conclusion Our protocol of hypofractionated palliative radiotherapy is effective palliating pain and bleeding, with acceptable toxicity. More patients and a longer follow-up of the survivors will provide us with more data on the improvement of the obstruction and no need for a colostomy, as well about time for symptomatic progression. EP-1649 Radiotherapy for osteolytic bone metastases from breast cancer: comparison with bone-modifying agent H. Tanaka 1 , M. Ito 1 , T. Yamaguchi 1 , K. Esaki 1 , M. Futamura 2 , F. Hyodo 1 , M. Matsuo 1 1 Gifu University, Radiology, Gifu, Japan 2 Gifu University, Surgical Onocology, Gifu, Japan Purpose or Objective Bone-modifying agents (BMA) are frequently used for treating patients diagnosed with bone metastases. BMAs are reportedly associated with a decrease in skeletal- related events (SREs). Although used to treat SRE, radiotherapy is primarily indicated for the prevention of pathological fractures. We evaluated the usefulness of radiotherapy for bone metastases treatment, in Oseteolytic bone metastases of the spine or pelvic bone from patients with breast cancer were evaluated in this study. Tomographic imaging was used to evaluate 35 lesions before and after radiotherapy, and 14 lesions before and after BMA treatment. Results Most lytic lesions treated with radiotherapy showed bone reformation (69%). Decreased fluorodeoxyglucose uptake and improvement of signal abnormalities on magnetic resonance imaging were also confirmed. Although some lytic lesions improved after using BMA without radiotherapy (21%), most remained unchanged or gradually worsened. The rate of improvement with radiotherapy was significantly higher than that with BMA (p=0.0461). PR or CR SD or PD RT ± BMA 24 11 BMA only 3 11 comparison with BMA. Material and Methods

Conclusion Radiotherapy is useful for bone metastases treatment. In particular, osteolytic or painful metastases should be treated with radiotherapy. EP-1650 Prevalence and Management of Pain In Tikur Anbessa Hospital Radiotherapy Center A.A. Woldemariam 1 , L. Gwyther 1 , N. Deyessa 1 , E. Kantelhardt 1 , G. Macchia 2 , S. CAMMELLI 3 , A.G. MORGANTI 3 1 Department of Radiotherapy, Black Lion Hospital, Addis- Ababa, Ethiopia 2 Radiotherapy Unit, Fondazione di Ricerca e Cura “Giovanni Paolo II”, Campobasso, Italy 3 Radiation Oncology Center- Dept. of Experimental- Diagnostic and Specialty Medicine – DIMES- University of Bologna, S.Orsola-Malpighi Hospital, BOLOGNA, Italy Purpose or Objective Prevalence of cancer is on a rise globally, in particular in developing countries. Pain is one of the most feared and burdensome symptoms in cancer patients and it remain a public health problem in cancer care in Ethiopia.The aim of this study was to identify the baseline prevalence of pain among in-patients at the general medical and oncology wards at a tertiary teaching hospital Tikur Anbassa Hospital in Addis Ababa, the pattern of pain management by the health care providers; and to assess the knowledge, attitude and practice of pain management of health care providers, Material and Methods This was a cross sectional, quantitative, observational study design conducted in Tikur Anbassa Hospital, in relation to knowledge and attitude of health care professionals in addressing pain in Tikur Anbassa Hospital. The characteristics of the pain and its management were assessed using the “Short Brief Pain inventory” (Cleeland C.S. 1991) Results 648 patients admitted to the oncology wards were interviewed out of which 265(40.9%) were males, and 383(59.1%) females. Of the total, 390 (60.2%) had experienced pain in the previous 24 hours. Out of the 390 patients with pain 161(41.28%) had severe pain. Out of the 390 patients with pain, 255(65.4%) were prescribed analgesics, and 135(34.6%) patients with pain were not given any analgesics. Out of the 161 patients with severe pain only 50(31.0%) were given morphine for their pain. The remaining 111 patients (69.0%) were given other analgesics. Considering recommendations of analgesic regimen for the hypothetical patient with severe cancer pain, 50% recommended morphine, the rest recommended NSAIDs Tramadol, and paracetamol. 50 % of prescriptions were for oral medication and 50% for parental medication. Conclusion Pain is highly prevalent and undertreated in cancer patients at the oncology center at TASH. Health care